I agree.
If you believe that the market will become competitive (say, more than 4 players including Apotex, Apicore, Reddy's and GSK....), then Reddy's will have to buy out the ACL Fonda business IMHO. Otherwise, they essentially face a much higher COGS and lower final margin (on total sales) than competitors.
Reddy's are not at all interested in the Oncology business (IMHO), which I suspect they have discussed with ACL as part of a longer term strategy (again IMHO).
I hope this takes a longer, rather than shorter time to play out as it is pretty likely that IMHO the Fonda market will grow faster than current market expectations as scripts are redirected from Lovenox etc to Fonda now that the price differential has begun to normalise.
- Forums
- ASX - By Stock
- TSN
- let's be realistic...
let's be realistic..., page-3
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NEWS
First paediatric clinical site activated – major recruitment milestone and key appointment announced
NEWS
Biotech innovator secures $5.5M R&D tax incentive refund – major boost for cutting-edge programs
TSN (ASX) Chart |
Day chart unavailable